The biologics market size is expected to grow around $320 billion by 2021 growing at double digit compound annual growth rate (CAGR). The growth in the biologics market is mainly due to government initiatives for the research and development of biopharmaceutical drugs, increasing healthcare access among developing and underdeveloped nations, and rising mergers and acquisitions in the biologics market.
Major trends witnessed in the biologics market over the historic period include increasing demand for biologics in the treatment of complex diseases, rising development of next generation biologics and revised FDA regulations facilitating biologics drug development.
Download Sample Report On Biologics Market At
The major mergers and acquisition in market has helped the big pharma companies to overcome the obstacles in R&D productivity. As a result, currently the pipelines of major companies like AstraZeneca, Sanofi have biological drugs, constituting nearly 30-40%, in the clinical stage.
ADMA Biologics, Inc. acquired Therapy Business of Biotest Pharmaceuticals Corporation, a 50% minus one share of ADMA. The deal includes two U.S. Food and Drug Administration (FDA) licensed products, Nabi-HB (Hepatitis B Immune Globulin, Human) and BIVIGAM (Immune Globulin Intravenous, Human), manufacturing and testing operations with two facilities in Boca Raton, Florida. ADMA also received $27.5 million in cash of which $15.0 million is in the form of a loan from Biotest Pharmaceuticals Corporation.
Order Biologics Market Report At
About The Business Research Company
The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: [email protected]
Follow us on Linkedin: https://in.linkedin.com/company/the-business-research-company